
|Articles|January 4, 2007
Repeated dosing of radiopharmaceutical found safe, effective in PCa patients with bone mets
Repeated doses of the targeted radiopharmaceutical samarium Sm-153 lexidronam injection (Quadramet) are a safe and effective treatment option in patients with painful bone metastases secondary to prostate cancer, according to a multicenter, phase IV study published recently in the online edition of Cancer.
Advertisement
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
NDV-01 produces robust 9-month results in high-risk NMIBC
2
Gemcitabine intravesical system delivers high 12-month DFS in papillary-only NMIBC
3
SUO 2025 data confirm IsoPSA accuracy independent of mpMRI use
4
SYNC-T demonstrates high bone metastasis resolution in phase 1 cohort
5


















